Wolverine Venture Fund
The world’s first student-run venture capital fund.
Organized by MBA students and graduate students from life sciences and biomedical engineering. You’ll source, analyze, and perform due diligence on investments in Series A through C venture capital rounds. You’ll work with other venture capital firms, company founders and management, and technical experts. You’ll also follow the progress of portfolio companies. The Fund has invested in companies that have gone public, been sold to strategic buyers, or failed. Many students go on to work in the venture capital industry.
Application Opens: AUG 28, 2026
Application Closes: SEP 9, 2026 @ 11:59 PM
If you have any questions before submitting your application, we will be holding drop-in hours at the following dates and times:
- September 3rd from 5:00-6:00 PM, Zoom Link
- September 4th from 4:00-5:30 PM, Winter Garden
Portfolio
Company Description: Digital Insurance platform for Property Developers
Vertical: FinTech
Year In: 2020
Company Description: Precision Diagnostics Software for cardiovascular disease
Vertical: Health Tech (SaaS)
Year In: 2020
Company Description: Developer of software enabling more efficient use of EV charging stations
Vertical: Mobility
Year In: 2020
Company Description: Commercializing a focused ultrasound ablation technique called histotripsy
Vertical: Medical Devices
Year In: 2017
Company Description: Provider of clinical performance analytics software
Vertical: Health Technology (SaaS)
Year In: 2013
Company Description: Developer of 3D whole-breast tomographic ultrasound imaging
Vertical: Medical Devices
Year In: 2010
Company Description: End-to-end retail promotion management and reporting
Vertical: Productivity Software (SaaS)
Year In: 2010
Company Description: Provider of on-demand cloud-based communications and collaboration services
Vertical: Productivity Software (SaaS)
Year In: 2008
Company Description: Developer of small molecule therapeutics for autoimmune disease and cancer
Vertical: Biotech
Year In: 2008
Company Description: Developer of vaccines designed to prevent respiratory diseases and offer mucosal immunity
Vertical: Biotech
Year In: 2006
Acquired by Qiagen
Acquired by Becton Dickinson
IPO at $13/share
Acquired by IBM
Acquired by KKR / XVP Water Partners
Merged with nLight, IPO at $16/share
Acquired by IDT
Acquired
Fund Members
Curran Aiyer
MBA ’27
Grace Aleck
PhD
Camilla Bendetti
Managing Director
MBA ’27
Sathvik Bhat
Director of Recruitment
PhD
Aaron Brodkey
Director of Deal Flow
MBA ’27
Sanjeet Choudhary Kakarla
MBA ’27
Stacy Damschroder
MBA ’28
Amani Djouadi
PhD
Roderick Emanuel
Director of Education
MBA ’27
Yiting Fei
MBA ’28
Mahnoor N. Gondal
Director of Deal Flow
PhD
Ruofan Hao
PhD
Ava Harb
Director of Portfolio Management
MBA ’27
Justin Hawkins
MBA’28
Elisabeth Jahnke
MBA ’27
Maria Jennings
PhD
Sincere (Yicheng) Kang
PhD
Ping Kao
MBA ’28
Sanya Kataria
MBA
Saachi Kheterpal
PhD
Kyoungmo Koo
PhD
Zeynep Deniz Lal
PhD
Liam Matthews
Managing Director
PhD
Arun Maran
MBA ’28
Clare Martin
PhD
James Noyes
MBA ’28
Ifedayo Omotunde
Director of Education
MBA ’27
Christopher Patsalis
PhD
Yulu Peng
PhD
Andrew Puglise
PhD
Sahil Patel
MBA ’27
Owen Pollock
Director of Recruitment
MBA ’27
Andrew Quinn
MBA ’27
Molly Rathore
MBA
Eric Roman
PhD
Troy Rzeznikiewicz
MBA ’28
Jett Stad
PhD
David Schrader
MBA ’27
Lueda Shemitraku
MBA ’28
Braylen Stevens
Director of Investor Relations
MBA ’27
Aaron Sussman
MBA ’28
Sanjana Vijay Vaidyanathan
MBA ’27
Tyler Willis
PhD
Evelyn Zhu
PhD
Chuwen Zheng
PhD
